利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

32 条记录 (耗时 0.04 秒)

    Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
    7.
    发明授权
    Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau 有权
    通过测量淀粉样蛋白来帮助诊断阿尔茨海默病的方法 肽（x-≥41）和tau

    公开(公告)号：US07811769B2

    公开(公告)日：2010-10-12

    申请号：US10879958

    申请日：2004-06-28

    申请人： Peter A. Seubert ,  Carmen Vigo-Pelfrey ,  Dale B. Schenk ,  Robin Barbour

    发明人： Peter A. Seubert ,  Carmen Vigo-Pelfrey ,  Dale B. Schenk ,  Robin Barbour

    IPC分类号： G01N33/53

    CPC分类号： C07K16/18 ,  C07K14/4711 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2500/00 ,  G01N2800/2821 ,  Y10S436/811

    摘要： This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-β peptide (x−≧41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis. Other methods involve measuring the amounts of both Aβ(x−≧41) and tau. Low levels of Aβ(x−≧41) and high levels of tau are a positive indicator of Alzheimer's disease, while high levels of Aβ(x−≧41) and low levels of tau are a negative indication of Alzheimer's disease.

    摘要翻译： 本发明提供了有助于诊断阿尔茨海默病的方法。 该方法涉及测量淀粉样蛋白的量 肽（x-≧41）在患者的脑脊液中。 高水平的肽通常与阿尔茨海默病的诊断不一致。 低水平的肽与疾病一致，并且与其他检测可以提供阳性诊断。 其他方法包括测量A＆Bgr（x-≥41）和tau的量。 低水平的A＆bgr（x-≧41）和高水平的tau是阿尔茨海默病的阳性指标，而高水平的A＆bgr（x-≧41）和低水平的tau是阿尔茨海默氏病的阴性指标。

    Testing compounds for effects on synaptophysin in transgenic mice expressing an Alzheimer's disease FAD DNA sequence
    8.
    发明授权
    Testing compounds for effects on synaptophysin in transgenic mice expressing an Alzheimer's disease FAD DNA sequence 有权
    测试化合物对表达阿尔茨海默病FAD DNA序列的转基因小鼠中突触素的影响

    公开(公告)号：US07186881B2

    公开(公告)日：2007-03-06

    申请号：US10746473

    申请日：2003-12-23

    申请人： Kate Dora Games ,  Dale B. Schenk ,  Lisa C. McConlogue ,  Peter A. Seubert ,  Russell E. Rydel

    发明人： Kate Dora Games ,  Dale B. Schenk ,  Lisa C. McConlogue ,  Peter A. Seubert ,  Russell E. Rydel

    IPC分类号： A01K67/00 ,  A01K67/027 ,  G01N33/00

    CPC分类号： C07K14/4711 ,  A01K67/0275 ,  A01K67/0276 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/075 ,  A01K2227/00 ,  A01K2267/0312 ,  A01K2267/0356 ,  C07K2319/02 ,  C12N15/8509

    摘要： The construction of transgenic animal models of human Alzheimer's disease, and methods of using the models to screen potential Alzhe## disease therapeutics, are described. The models are characterized by pathologies similar to pathologies observed in Alzheimer's disease, based on expression of all three forms of the β-amyloid precursor protein (APP), APP695, APP751, and APP770, as well as various point mutations based on naturally occurring mutations, such as the London and Indiana familial Alzheimer's disease (FAD) mutations at amino acid 717, predicted mutations in the APP gene, and truncated forms of APP that contain the Aβ region. Animal cells can be isolated from the transgenic animals or prepared using the same constructs with standard techniques such as lipofection or electroporation. The transgenic animals, or animal cells, are used to screen for compounds altering the pathological course of Alzheimer's disease as measured by their effect on the amount of APP, β-amyloid peptide, and numerous other Alzheimer's disease markers in the animals, the neuropathology of the animals, as well as by behavioral alterations in the animals.

    摘要翻译： 描述了人类阿尔茨海默氏病的转基因动物模型的构建，以及使用该模型筛选潜在的阿尔茨海默病治疗剂的方法。 基于所有三种形式的β-淀粉样蛋白前体蛋白（APP），APP695，APP751和APP770的表达以及基于天然存在的突变的各种点突变，模型的特征在于类似于在阿尔茨海默病中观察到的病理学的病理学 ，例如氨基酸717处的伦敦和印第安纳家族性阿尔茨海默病（FAD）突变，APP基因中预测的突变和含有Abeta区的APP的截短形式。 可以从转基因动物中分离动物细胞，或者使用具有标准技术如脂质转染或电穿孔的相同构建体来制备动物细胞。 转基因动物或动物细胞用于筛选改变阿尔茨海默氏病病理过程的化合物，如通过其对动物中APP，β-淀粉样蛋白肽和许多其他阿尔茨海默氏病标志物的量的影响所测量的，神经病理学 动物，以及动物的行为改变。

    Methods and compositions for the detection of soluble .beta.-amyloid peptide
    10.
    发明授权
    Methods and compositions for the detection of soluble .beta.-amyloid peptide 失效
    检测可溶性β-淀粉样肽的方法和组合物

    公开(公告)号：US5837672A

    公开(公告)日：1998-11-17

    申请号：US456347

    申请日：1995-06-01

    申请人： Dale B. Schenk ,  Michael G. Schlossmacher ,  Dennis J. Selkoe ,  Peter A. Seubert ,  Carmen Vigo-Pelfrey

    发明人： Dale B. Schenk ,  Michael G. Schlossmacher ,  Dennis J. Selkoe ,  Peter A. Seubert ,  Carmen Vigo-Pelfrey

    IPC分类号： G01N33/68 ,  A61K31/00 ,  A61K38/00

    CPC分类号： G01N33/6896 ,  G01N2800/2821 ,  Y10S436/811

    摘要： Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of .beta.AP in the animal or culture medium observed. It has been found that elevated levels of .beta.AP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a .beta.AP-related condition in a patient, such as Alzheimer's Disease. Methods for diagnosing and monitoring .beta.AP-related conditions comprise measuring the levels of .beta.AP in such body fluids from a patient.

    摘要翻译： 可溶性β-淀粉样蛋白肽（beta AP）在生物液体中以非常低的浓度测量，通常在0.1ng / ml至10ng / ml的范围内。 动物或培养细胞的条件培养基中的βAP浓度的测量可用于药物筛选，其中将测试化合物施用于动物或暴露于培养的细胞，并观察动物或培养基中βAP的积累。 已经发现体液中的βAP水平升高如血液和脑脊液与患者中诸如阿尔茨海默氏病之类的βAP相关病症的存在相关。 用于诊断和监测β-AP相关病症的方法包括测量来自患者的这种体液中的βAP的水平。